tradingkey.logo
tradingkey.logo
Search

Aprea Therapeutics Inc

APRE
Add to Watchlist
0.632USD
+0.004+0.70%
Close 07-24 16:00ETQuotes delayed by 15 min
7.57MMarket Cap
LossP/E TTM

APRE Income Statement

You can find the annual or quarterly income statement of Aprea Therapeutics Inc here for insights into the performance and operational efficiency of Aprea Therapeutics Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q4
FY2020Q3
FY2020Q2
FY2020Q1
FY2019Q4
FY2019Q3
FY2019Q2
FY2019Q1
FY2018Q4
FY2018Q3
Total revenue
-100.00%0.00
-98.38%3.34K
-99.48%1.85K
-78.97%118.11K
-57.31%162.46K
1362.29%205.82K
11.00%354.62K
124.91%561.57K
--380.57K
--14.07K
--319.47K
--249.69K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Revenue
-100.00%0.00
-98.38%3.34K
-99.48%1.85K
-78.97%118.11K
-57.31%162.46K
1362.29%205.82K
11.00%354.62K
124.91%561.57K
--380.57K
--14.07K
--319.47K
--249.69K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Operating expenses
-19.25%3.43M
-22.89%2.65M
-29.93%3.12M
-20.47%3.51M
20.33%4.25M
-6.97%3.43M
15.86%4.45M
13.00%4.41M
-23.63%3.53M
39.12%3.69M
-8.52%3.84M
-82.62%3.90M
-42.75%4.62M
-66.13%2.65M
-55.46%4.20M
124.51%22.45M
-20.75%8.07M
-44.96%7.83M
-22.92%9.43M
-30.96%10.00M
-14.17%10.19M
18.73%14.22M
69.49%12.23M
143.85%14.48M
169.36%11.87M
144.52%11.98M
146.30%7.22M
--5.94M
--4.41M
--4.90M
--2.93M
R&D expenses
-35.11%1.61M
-57.24%1.01M
-42.42%1.64M
-25.24%1.91M
55.16%2.48M
15.32%2.36M
34.10%2.85M
16.12%2.56M
27.36%1.60M
284.96%2.05M
89.93%2.12M
-67.66%2.20M
-69.27%1.26M
-88.09%531.41K
-81.42%1.12M
2.36%6.81M
-39.54%4.09M
-52.16%4.46M
-31.34%6.02M
-37.78%6.65M
-25.64%6.76M
15.99%9.33M
78.42%8.76M
147.56%10.69M
147.28%9.10M
82.98%8.04M
112.85%4.91M
--4.32M
--3.68M
--4.39M
--2.31M
Depreciation, depletion, and amortization
-0.02%5.43K
0.02%5.43K
0.00%5.43K
2.34%5.43K
-11.82%5.43K
8.86%5.43K
279.12%5.43K
2267.86%5.30K
1401.71%6.16K
--4.99K
-97.67%1.43K
-99.65%224.00
-99.36%410.00
----
-11.63%61.37K
5.74%63.69K
-16.10%63.77K
15.99%65.99K
22.50%69.44K
24.83%60.24K
12.14%76.00K
9.72%56.89K
-8.28%56.69K
1757.43%48.26K
142.72%67.77K
2788.86%51.85K
2637.25%61.81K
--2.60K
--27.92K
--1.79K
--2.26K
Other operating expenses
--0.00
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Operating profit
16.04%-3.43M
18.07%-2.64M
23.91%-3.12M
11.94%-3.39M
-29.71%-4.09M
12.21%-3.23M
-16.30%-4.10M
-5.35%-3.85M
31.86%-3.15M
-38.59%-3.67M
16.13%-3.52M
83.73%-3.65M
42.75%-4.62M
66.13%-2.65M
55.46%-4.20M
-124.51%-22.45M
20.75%-8.07M
44.96%-7.83M
22.92%-9.43M
30.96%-10.00M
14.17%-10.19M
-18.73%-14.22M
-69.49%-12.23M
-143.85%-14.48M
-169.36%-11.87M
-144.52%-11.98M
-146.30%-7.22M
---5.94M
---4.41M
---4.90M
---2.93M
Net non-operating interest income (expenses)
Non-operating interest income
-34.16%134.78K
-56.79%118.66K
-56.80%150.67K
-53.44%178.03K
-27.76%204.73K
-11.49%274.63K
8.57%348.74K
13.73%382.37K
10.53%283.40K
27.65%310.29K
112.55%321.21K
540.53%336.22K
12909.13%256.41K
--243.08K
--151.12K
--52.49K
--1.97K
----
----
----
----
-97.21%4.74K
----
--2.68K
--224.44K
8494300.00%169.89K
----
----
----
--2.00
--4.00
Non-operating interest expense
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--33.00
--588.00
--1.06K
----
----
----
----
----
--6.10K
--4.09K
--3.35K
----
----
Gains from sale of securities
114.89%7.71K
-115.37%-8.70K
83.97%-5.69K
-429.33%-29.12K
-192.22%-51.80K
172.02%56.62K
-1132.43%-35.49K
-109.76%-5.50K
507.16%56.18K
-133.99%-78.61K
-111.83%-2.88K
-63.53%56.36K
-110.13%-13.80K
-147.88%-33.60K
211.17%24.35K
161.13%154.57K
-73.91%136.21K
105.98%70.17K
70.62%-21.91K
86.62%-252.84K
-76.78%521.98K
7.05%-1.17M
-107.65%-74.56K
-377.87%-1.89M
140.18%2.25M
-674.81%-1.26M
569.80%975.03K
--680.06K
--935.92K
--219.70K
---207.54K
Special income (expenses)
----
----
----
----
----
----
----
----
----
--0.00
--0.00
100.00%0.00
----
--0.00
--0.00
---76.02M
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Other non-operating income (expenses)
----
--77.50K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Income before tax
16.39%-3.29M
15.17%-2.46M
21.44%-2.97M
6.66%-3.24M
-39.95%-3.93M
15.93%-2.89M
-18.08%-3.78M
-6.47%-3.47M
35.84%-2.81M
-40.99%-3.44M
20.38%-3.20M
96.68%-3.26M
44.81%-4.38M
68.51%-2.44M
57.42%-4.02M
-858.52%-98.26M
17.91%-7.94M
49.62%-7.76M
23.26%-9.45M
37.37%-10.25M
-2.86%-9.67M
-17.75%-15.39M
-97.11%-12.32M
-211.03%-16.37M
-170.50%-9.40M
-179.35%-13.07M
-99.14%-6.25M
---5.26M
---3.48M
---4.68M
---3.14M
Income tax
--0.00
----
--0.00
----
----
--0.00
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Income after tax
16.39%-3.29M
15.17%-2.46M
21.44%-2.97M
6.66%-3.24M
-39.95%-3.93M
15.93%-2.89M
-18.08%-3.78M
-6.47%-3.47M
35.84%-2.81M
-40.99%-3.44M
20.38%-3.20M
96.68%-3.26M
44.81%-4.38M
68.51%-2.44M
57.42%-4.02M
-858.52%-98.26M
17.91%-7.94M
49.62%-7.76M
23.26%-9.45M
37.37%-10.25M
-2.86%-9.67M
-17.75%-15.39M
-97.11%-12.32M
-211.03%-16.37M
-170.50%-9.40M
-179.35%-13.07M
-99.14%-6.25M
---5.26M
---3.48M
---4.68M
---3.14M
Net income from continuous operations
16.39%-3.29M
15.17%-2.46M
21.44%-2.97M
6.66%-3.24M
-39.95%-3.93M
15.93%-2.89M
-18.08%-3.78M
-6.47%-3.47M
35.84%-2.81M
-40.99%-3.44M
20.38%-3.20M
96.68%-3.26M
44.81%-4.38M
68.51%-2.44M
57.42%-4.02M
-858.52%-98.26M
17.91%-7.94M
49.62%-7.76M
23.26%-9.45M
37.37%-10.25M
-2.86%-9.67M
-17.75%-15.39M
-97.11%-12.32M
-211.03%-16.37M
-170.50%-9.40M
-179.35%-13.07M
-99.14%-6.25M
---5.26M
---3.48M
---4.68M
---3.14M
Net income attributable to controlling interests
16.39%-3.29M
15.17%-2.46M
21.44%-2.97M
6.66%-3.24M
-39.95%-3.93M
15.93%-2.89M
-18.08%-3.78M
-6.47%-3.47M
35.84%-2.81M
-40.99%-3.44M
20.38%-3.20M
96.68%-3.26M
44.81%-4.38M
68.51%-2.44M
57.42%-4.02M
-858.52%-98.26M
17.91%-7.94M
49.62%-7.76M
23.26%-9.45M
37.37%-10.25M
-2.86%-9.67M
-17.75%-15.39M
-97.11%-12.32M
-211.03%-16.37M
-170.50%-9.40M
-179.35%-13.07M
-99.14%-6.25M
---5.26M
---3.48M
---4.68M
---3.14M
Net income attributable to common shareholders
16.39%-3.29M
15.17%-2.46M
21.44%-2.97M
6.66%-3.24M
-39.95%-3.93M
15.93%-2.89M
-18.08%-3.78M
-6.47%-3.47M
35.84%-2.81M
-40.99%-3.44M
20.38%-3.20M
96.68%-3.26M
44.81%-4.38M
68.51%-2.44M
57.42%-4.02M
-858.52%-98.26M
17.91%-7.94M
49.62%-7.76M
23.26%-9.45M
37.37%-10.25M
-2.86%-9.67M
-17.75%-15.39M
-97.11%-12.32M
-211.03%-16.37M
-170.50%-9.40M
-179.35%-13.07M
-99.14%-6.25M
---5.26M
---3.48M
---4.68M
---3.14M
Basic earnings per share
65.88%-0.22
34.37%-0.32
26.78%-0.47
8.90%-0.53
1.98%-0.66
47.25%-0.49
25.75%-0.64
33.08%-0.58
50.17%-0.67
-0.34%-0.92
63.06%-0.86
98.99%-0.87
81.47%-1.34
87.25%-0.92
73.92%-2.32
-796.14%-86.72
20.59%-7.25
50.44%-7.20
23.43%-8.90
37.61%-9.68
-2.21%-9.13
-47.77%-14.53
-78.72%-11.63
-183.07%-15.51
-146.81%-8.93
-101.82%-9.83
-99.13%-6.51
---5.48
---3.62
---4.87
---3.27
Diluted earnings per share
65.88%-0.22
34.37%-0.32
26.78%-0.47
8.90%-0.53
1.98%-0.66
47.25%-0.49
25.75%-0.64
33.08%-0.58
50.17%-0.67
-0.34%-0.92
63.06%-0.86
98.99%-0.87
81.47%-1.34
87.25%-0.92
73.92%-2.32
-796.14%-86.72
20.59%-7.25
50.44%-7.20
23.43%-8.90
37.61%-9.68
-2.21%-9.13
-47.77%-14.53
-78.72%-11.63
-183.07%-15.51
-146.81%-8.93
-101.82%-9.83
-99.13%-6.51
---5.48
---3.62
---4.87
---3.27
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Aprea Therapeutics Inc's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing APRE stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Aprea Therapeutics Inc's revenue at year end?

Aprea Therapeutics Inc reported 285.76K in revenue for fiscal year 2025, up from 1.50M in the previous year.

What was Aprea Therapeutics Inc's net income for the year?

Aprea Therapeutics Inc posted -12.60M in net income for fiscal year 2025.

How much net income did Aprea Therapeutics Inc post in the last quarter?

Aprea Therapeutics Inc reported -3.29M in net income for the latest quarter。

What was Aprea Therapeutics Inc's annual operating profit?

Aprea Therapeutics Inc's operating income was -13.23M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.